| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA340: Ustekinumab for treating active psoriatic arthritis (replaced TA313) |
|
Medicine details |
|
| Medicine name | ustekinumab (Stelara®) |
| Formulation | 45 mg solution for injection |
| Reference number | 1326 |
| Indication | Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease modifying anti-rheumatic drug therapy has been inadequate |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/09/2013 |
| NICE guidance | TA340: Ustekinumab for treating active psoriatic arthritis (replaced TA313) |